Latest Conference Articles

At the opening session of the Society of Dermatology Nurse Practitioners Annual Symposium, Kathleen Haycraft, DNP, FNP-BC, DCNP, FAANP, shared insights into the state of the profession and what’s ahead.

In this video interview, Andrew Blauvelt, MD, MBA, dermatologist and clinical researcher at the Oregon Medical Research Center, highlights his key takeaways from his presentation at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee.

The Society of Dermatology Nurse Practitioners is having its annual conference this weekend, starting April 22 through 23 with a certification review course happening April 24 to 25, in Nashville, Tennessee.

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, talks about how education of patients is so important, the upcoming parts of the AAD guidelines to look forward to, and more.

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

A RAD conference abstract presentation highlights the demographic, prevalence, and comorbidity data for adults with atopic dermatitis.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research, explores the hidden burdens of itch that many pediatric patients and parents have to deal with on a daily basis. She expanded on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference was held from April 9 to 11 in Baltimore, Maryland

In her talk at the Revolutionizing Atopic Dermatitis Conference, Madison Cook, BS, gives tips on how to increase accountability, common barriers to overcome with patients, and more.

What do topical PDE4 inhibitors bring to the treatment toolbox? Which patients are likely to get the most use out of them? Robert Sidbury, MD, MPH, answers these questions and more in this video interview.

An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.

Experts take a closer look at when to watch, and what to watch for in patients on JAK inhibitors.

Expert panelists discussed the pros, cons, and unknowns of the fast-growing roster of new AD treatments in a session at the 4th Annual Revolutionizing Atopic Dermatitis Conference held April 9 to 11, 2022 in Baltimore, Maryland.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research dives into the importance of the results from their recently released study.

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.

The Revolutionizing Atopic Dermatitis conference begins with presentations focused on new treatments, data, and more in atopic dermatitis.

LEO Pharma presented long-term data from an interim analysis of its ECZTEND 5-year extension trial, showing no new safety signals.

What are the best post- and pre-lightening products and strategies for optimal results on all skin types? Renata Block, president of the Society of Dermatology Physician Assistants, walked through her pearls in this interview at the American Academy of Dermatology 2022 Annual Meeting.

Renata Block, MMS, PA-C, president of the Society of Dermatology Physician Assistants (PAs) talked with Dermatology Times® at the American Academy of Dermatology 2022 Annual Meeting about the broadening opportunities for these advanced health care providers to help fill the demand gap for treatment of skin and hair disorders as well as aesthetic services.

A poster from the 2022 American Academy of Dermatology Annual Meeting gathered the real-world data around patients using dupilumab to treat atopic dermatitis.

A poster from the 2022 American Academy of Dermatology Annual Meeting presented subgroup analyses from the Effisayil 1 study that showed the efficacy of spesolimab was consistent across all prespecified patient populations, including those with or without IL-36RN mutations.

VisualDX uses diverse imagery to help increase knowledge of disease manifestations in a range of skin types.

In this fourth part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, talks about what to look forward to in treatment and clinical trials of merkel cell carcinoma (MCC).

Medications, plants, and more may play a significant role in systemic contact dermatitis.

In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.

The company announced its collaboration with the American Academy of Dermatology on, “Pathways: Inclusivity in Dermatology,” to increase the number of practicing dermatologists in the Black, Latino, and Indigenous communities in medicine over the next 5 years.

Klint Peebles, MD, FAAD, breaks down the core terminology for LGBTQ/SGD individuals so all patients can feel understood when entering the exam room.

In a presentation at the recent AAD annual meeting, Diane M. Thiboutot, MD, discusses the potential risks of antibiotic resistance in acne management.

What’s new in body skin care? According to Neil Sadick, MD, FACP, FAACS, FACph, FAAD, all fingers point to these methods.